Indisulam

 CAS No.: 165668-41-7  Cat No.: BP-900060  Purity: ≥98% (HPLC) 4.5  

Indisulam is a carbonic anhydrase inibitor. It is a molecular glue that degrades mRNA splicing factor RBM39.

Indisulam

Structure of 165668-41-7

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
Molecular Glue
Molecular Formula
C14H12ClN3O4S2
Molecular Weight
385.84
Appearance
White to pink solid powder

* For research and manufacturing use only. Not for human or clinical use.

SizePriceStockQuantity
100 mg $399 In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

  • mg to g scale for early stage;
  • CDMO and CMO support.
  • 24/7 customer service;
  • 100% quality assurance;
  • Efficient global delivery;
  • Over 95% customer satisfaction.
Popular Publications Citing BOC Sciences Products
Purity
≥98% (HPLC)
Solubility
DMSO:38.58mg/mL
Appearance
White to pink solid powder
Application
Antineoplastic Agents
ShelfLife
>2 years if stored properly
Storage
Store at -20°C
Shipping
Room temperature in continental US; may vary elsewhere.
IUPACName
4-N-(3-chloro-1H-indol-7-yl)benzene-1,4-disulfonamide
Synonyms
E7070; E 7070; E-7070; ER35744; ER 35744; ER-35744; D04522; Indisulam
Chemical Name
N1-(3-Chloro-1H-indol-7-yl)-1,4-benzenedisulfonamide
InChI Key
InChI=1S/C14H12ClN3O4S2/c15-12-8-17-14-11(12)2-1-3-13(14)18-24(21,22)10-6-4-9(5-7-10)23(16,19)20/h1-8,17-18H,(H2,16,19,20)
InChI
SETFNECMODOHTO-UHFFFAOYSA-N
Canonical SMILES
NS(=O)(C1=CC=C(S(=O)(NC2=CC=CC3=C2NC=C3Cl)=O)C=C1)=O
Biological Activity
Acts as a molecular glue to induce proteosomal degradation of mRNA splicing factor RBM39 (also designated CAPERα, HCC1, FSAP59, and RNPC2), via binding to DCAF15. Acts as a pre-mRNA splicing modulator (SPLAMs; splicing inhibitor sulfonamides), causes aberrant pre-mRNA splicing. Suppresses proliferation of cancer cell lines. Reduces viability of HCT-116 cells (IC50 = 0.56 μM). Induces cell cycle arrest in the G1 phase in cancer cell lines. Also a high affinity carbonic anhydrase isozyme XII (hCA XII) inhibitor (Ki = 3.0-5.7 nM).
1.Sulfonamide inhibition studies of the δ-carbonic anhydrase from the diatom Thalassiosira weissflogii.
Vullo D1, Del Prete S2, Osman SM3, De Luca V2, Scozzafava A1, Alothman Z3, Supuran CT4, Capasso C5. Bioorg Med Chem Lett. 2014 Jan 1;24(1):275-9. doi: 10.1016/j.bmcl.2013.11.021. Epub 2013 Nov 20.
The δ-carbonic anhydrase (CA, EC 4.2.1.1) TweCA from the marine diatom Thalassiosira weissflogii has recently been cloned, purified and its activity/inhibition with anions investigated. Here we report the first sulfonamide/sulfamate inhibition study of a δ-class CA. Among the 40 such compounds investigated so far, 3-bromosulfanilamide, acetazolamide, ethoxzolamide, dorzolamide and brinzolamide were the most effective TweCA inhibitors detected, with KIs of 49.6-118nM. Many simple aromatic sulfonamides as well as dichlorophenamide, benzolamide, topiramate, zonisamide, indisulam and valdecoxib were medium potency inhibitors, (KIs of 375-897nM). Saccharin and hydrochlorothiazide were ineffective inhibitors of the δ-class enzyme, with KIs of 4.27-9.20μM. The inhibition profile of the δ-CA is very different from that of α-, β- and γ-CAs from different organisms. Although no X-ray crystal structure of this enzyme is available, we hypothesize that as for other CA classes, the sulfonamides inhibit the enzymatic activity by binding to the Zn(II) ion from the δ-CA active site.
2.Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic bacterium Colwellia psychrerythraea.
Vullo D1, De Luca V2, Del Prete S3, Carginale V2, Scozzafava A1, Osman SM4, AlOthman Z4, Capasso C5, Supuran CT6. Bioorg Med Chem Lett. 2016 Feb 15;26(4):1253-9. doi: 10.1016/j.bmcl.2016.01.023. Epub 2016 Jan 11.
The Antarctic bacterium Colwellia psychrerythraea encodes for a γ-class carbonic anhydrase (CA, EC 4.2.1.1), which was cloned, purified and characterized. The enzyme (CpsCAγ) has a moderate catalytic activity for the physiologic reaction of CO2 hydration to bicarbonate and protons, with a kcat 6.0×10(5)s(-1) and a kcat/Km of 4.7×10(6)M(-1)s(-1). A series of sulfonamides and a sulfamate were investigated as inhibitors of the new enzyme. The best inhibitor was metanilamide (KI of 83.5nM) followed by indisulam, valdecoxib, celecoxib, sulthiame and hydrochlorothiazide (KIs ranging between 343 and 491nM). Acetazolamide, methazolamide as well as other aromatic/heterocyclic derivatives showed inhibition constants between 502 and 7660nM. The present study may shed some more light regarding the role that γ-CAs play in the life cycle of psychrophilic bacteria as the Antarctic one investigated here, by allowing the identification of inhibitors which may be useful as pharmacologic tools.
3.Polypharmacology of sulfonamides: pazopanib, a multitargeted receptor tyrosine kinase inhibitor in clinical use, potently inhibits several mammalian carbonic anhydrases.
Winum JY1, Maresca A, Carta F, Scozzafava A, Supuran CT. Chem Commun (Camb). 2012 Aug 25;48(66):8177-9. doi: 10.1039/c2cc33415a. Epub 2012 Jun 26.
Pazopanib, a new, multi-targeted tyrosine kinase inhibitor (TKI) used clinically for the treatment of several types of tumors, incorporates a primary sulfonamide moiety normally associated with the inhibition of the metallo enzyme carbonic anhydrase (CA, EC 4.2.1.1). Here we show that pazopanib and related sulfonamides such as indisulam, acetazolamide or ureido-substituted peptidomimetic benzenesulfonamides are low nanomolar inhibitors of many of the fifteen human isoforms hCA I-XIV. These data indicate that in addition to the TK inhibitory action, pazopanib may exert antitumor/antimetastatic effects also due to the potent inhibition of the tumor-associated, hypoxia-inducible enzymes CA IX and XII.
4.DNA cloning, characterization, and inhibition studies of an α-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae.
Del Prete S1, Isik S, Vullo D, De Luca V, Carginale V, Scozzafava A, Supuran CT, Capasso C. J Med Chem. 2012 Dec 13;55(23):10742-8. doi: 10.1021/jm301611m. Epub 2012 Dec 4.
We have cloned, purified, and characterized an α-carbonic anhydrase (CA, EC 4.2.1.1) from the human pathogenic bacterium Vibrio cholerae, VchCA. The new enzyme has significant catalytic activity, and an inhibition study with sulfonamides and sulfamates led to the detection of a large number of low nanomolar inhibitors, among which are methazolamide, acetazolamide, ethoxzolamide, dorzolamide, brinzolamide, benzolamide, and indisulam (KI values in the range 0.69-8.1 nM). As bicarbonate is a virulence factor of this bacterium and since ethoxzolamide was shown to inhibit the in vivo virulence, we propose that VchCA may be a target for antibiotic development, exploiting a mechanism of action rarely considered until now.

How does indisulam inhibit cell proliferation?

Indisulam inhibits cell proliferation by causing degradation of RBM39. Indisulam promotes an interaction between RBM39 and the DCAF15 E3 ligase substrate receptor, leading to RBM39 ubiquitination and proteasome-mediated degradation.

8/8/2022

How does indisulam inhibit carbonic anhydrase?

Indisulam causes G1/S transition to be blocked by inhibiting the activation of CDK2 and cyclin E.

8/8/2022

What is the mechanism of Indisulam to treat solid tumors?

Indisulam arrests cell cycle in the G1 phase, strongly inhibits carbonic anhydrase, a critical enzyme involved in many physiological processes and whose association with cancer became obvious in the last period, and markedly alters gene expression levels of at least 60 transcripts.

8/8/2022

Does it promote the degradation of any proteins?

It selectively targets RNA splicing factor RBM39 for proteosomal degradation via DCAF15-E3-ubiquitin ligase.

10/11/2023

Can you give me a brief introduction to its structure?

Indisulam is a chloroindole that is 3-chloro-1H-indole substituted by a [(4-sulfamoylphenyl)sulfonyl]nitrilo group.

10/11/2023

What are some of its receptor?

Carbonic anhydrase is its target.

10/11/2023

downregulate cyclin A

Indisulam disturbs and downregulates cyclin A, cyclin B, CDK2 and CDC2 in our study.

4/9/2017

inhibit cell growth

We found that Indisulam caused growth inhibition in cellular models of neuroblastoma.

4/9/2017

reduce tumour volume

We observed a near complete reduction in tumour volume by MR imaging after 7 days of Indisulam treatment compared to vehicle control.

4/9/2017

targeted splicing

We have used indisulam for a long time. it targets splicing by recruiting DCAF15 to induce RBM39 degradation.

24/8/2022

leading to cell death

This product works pretty well for our cell culture experiments. It causes cell cycle perturbation in the G1 phase in a time- and dose-dependent manner, potentially leading to cell death.

24/8/2022

antiproliferative effects

Indisulam works well in vitro, it has antiproliferative effects on a wide range of human tumor lines with HCT116 colorectal being the most sensitive and NCI-H596 non-small cell lung cancer (NSCLC) the most resistant (IC50s = 0.11 and 94 μg/ml, respectively).

24/8/2022

Stock concentration: *
Desired final volume: *
Desired concentration: *

L

* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2

* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O c22h30n40
g/mol
g

Related Product Recommendations

BOC Sciences Support

Please contact us with any specific requirements and we will get back to you as soon as possible.


  • Verification code

We invite you to contact us at or through our contact form above for more information about our services and products.

USA
  • International:
  • US & Canada (Toll free):
  • Email:
  • Fax:
UK
Germany
Inquiry Basket